A meta-analysis of salicylates for type 2 diabetes mellitus (Q38080017)

28 August 2017

0 references

A meta-analysis of salicylates for type 2 diabetes mellitus (English)

1 reference

28 August 2017

1 reference

Fang Fang

1

1 reference

28 August 2017

Yu Lu

2

1 reference

28 August 2017

De-lin Ma

3

1 reference

28 August 2017

Ting-ting Du

4

1 reference

28 August 2017

Shi-ying Shao

5

1 reference

28 August 2017

Xue-feng Yu

6

1 reference

28 August 2017

8 February 2013

1 reference

Journal of Huazhong University of Science and Technology. Medical Sciences

28 August 2017

1 reference

28 August 2017

33

1 reference

28 August 2017

1

1 reference

28 August 2017

1-14

1 reference

https://scigraph.springernature.com/pub.10.1007/s11596-013-1063-5

28 August 2017

0 references

cites work

Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Potential role of salicylates in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Aspirin for primary prevention of cardiovascular events in people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Reduction of blood fibrinolytic activity in diabetes mellitus by insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

21 January 2018

FIBRINOLYSIS IN OBESITY

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Inflammation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Aspirin and diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Salsalate improves glycemia and inflammatory parameters in obese young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

The effect of aspirin on the antiproteinuric properties of enalapril in microalbuminuric type 2 diabetic patients: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Lack of interference of aspirin in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Final report on the aspirin component of the ongoing Physicians' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

A Role for Prostaglandin E in Defective Insulin Secretion and Carbohydrate Intolerance in Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Increased secretion of insulin but unchanged secretion of growth hormone in hyperglycaemic type II diabetics treated with acetyl-salicylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Effect of sodium salicylate on hormonal responses to hypoglycaemia in type II diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Inhibition of NF-kappa B by sodium salicylate and aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

The effect of high-dose sodium salicylate on chronically elevated plasma nonesterified fatty acid-induced insulin resistance and β-cell dysfunction in overweight and obese nondiabetic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11596-013-1063-5

Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates.

21 January 2018

1 reference

12 December 2020

Invited comment on W. Ebstein: On the therapy of diabetes mellitus, in particular on the application of sodium salicylate

1 reference

12 December 2020

Is low-dose aspirin a useful adjuvant therapy in the treatment of NIDDM?

1 reference

12 December 2020

Effect of aspirin on glucose tolerance and insulin levels in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Acute effects of acetylsalicylic acid on blood glucose and insulin in non-insulin dependent diabetes.

1 reference

12 December 2020

Aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects

1 reference

12 December 2020

Effect of salicylate infusion on plasma-insulin and glucose tolerance in healthy persons and mild diabetics

1 reference

12 December 2020

Reappraisal of the hypoglycemic action of acetylsalicylate.

1 reference

12 December 2020

Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes

1 reference

12 December 2020

Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM

1 reference

12 December 2020

Blockade of chlorpropamide alcohol flush by aspirin

1 reference

12 December 2020

Tumor necrosis factor alpha: a key component of the obesity-diabetes link

1 reference

12 December 2020

Effects of nonsteroidal antiinflammatory drugs in conventional dosage on glucose homeostasis in patients with diabetes.

1 reference

12 December 2020

Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group

1 reference

12 December 2020

Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators

1 reference

12 December 2020

On the Treatment of Glycosuria and Diabetes Mellitus with Sodium Salicylate

1 reference

12 December 2020

Restoration of the acute insulin response by sodium salicylate. A glucose dose-related phenomenon

1 reference

12 December 2020

Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration

1 reference

12 December 2020

The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects

1 reference

12 December 2020

The effect of salicylate on plasma nonesterified fatty acids

1 reference

12 December 2020

Aspirin therapy in diabetes

1 reference

12 December 2020

A role for endogenous prostaglandins in defective glucose potentiation of nonglucose insulin secretagogues in diabetics

1 reference

12 December 2020

Insulin receptors and glucose homeostasis in type 2 diabetics influenced by acetyl-salicylic acid treatment

1 reference

12 December 2020

Fibrinolysis and body bulid. Interrelationships between blood fibrinolysis, body composition and parameters of lipid and carbohydrate metabolism

1 reference

12 December 2020

Aspirin and salicylate: An old remedy with a new twist

1 reference

12 December 2020

10.1007/S11596-013-1063-5

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1006556664

0 references

Fatcat ID

release_lwumsz7eqzfgpjp4sj6dwf5zqa

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lwumsz7eqzfgpjp4sj6dwf5zqa

24 November 2022

mapped directly with Wikidata item

1 reference